Operating Expenses
Acquired IPR&D Expense
Eli Lilly Acquired IPR&D Expense decreased by 62.8% to $584.00M in Q1 2026 compared to the prior quarter.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2025
Last reportedQ1 2026
Metric ID:
is_abbv_acquired_iprd_expenseHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $1.57B | $584.00M |
| QoQ Change | — | -62.8% |
| YoY Change | — | -62.8% |
Range$584.00M – $1.57B
Avg YoY Growth-62.8%
Median YoY Growth-62.8%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $1.57B | $153.80M | $655.70M | $528.80M | $584.00M |
| Total | $1.57B | — | — | — | $584.00M |
Acquired IPR&D Expense at Other Companies
Frequently Asked Questions
- What is Eli Lilly's acquired ipr&d expense?
- Eli Lilly (LLY) reported acquired ipr&d expense of $584.00M in Q1 2026.